Development of a monoclonal antibody to factor VIII C2 domain and its functional study

Zhen Yu Li, Yi Ming Zhao, Ning Zheng Dong, Fei Shen, Chang Geng Ruan

Research output: Contribution to journalArticlepeer-review


OBJECTIVE: To develop a monoclonal antibody (mAb) directed to FVIII C2 domain and investigate its effect on FVIII activity. METHODS: FVIII C2 protein was expressed in E. coli and purified. A murine antihuman FVIII C2 domain mAb SZ-132 was developed by standard hybridoma technology and characterized. In coagulation assays, different concentrations of SZ-132 were incubated with freshly collected pooled human plasma and the residual activity of FVIII and activated partial thromboplastin time (APTT) were determined. The effects of SZ-132 on rhFVIII binding to purified human vWF, phosphatidylserine (PS) and platelets were assessed by enzyme linked immunosorbent assays (ELISA). RESULTS: SZ-132 could inhibit FVIII procoagulant activity in a dose-dependent manner within the concentrations of 0-25 microg/ml and the FVIII activity was completely inhibited on above 25 microg/ml. It could also prevent rhFVIII from binding to vWF, PS and platelets. CONCLUSIONS: SZ-132 is a neutralizing mAb against FVIII C2 domain and can inhibit FVIII procoagulant activity by preventing FVIII from binding to vWF and PS.

Original languageEnglish
Pages (from-to)154-157
Number of pages4
JournalZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Issue number3
StatePublished - Mar 2009

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Development of a monoclonal antibody to factor VIII C2 domain and its functional study'. Together they form a unique fingerprint.

Cite this